Life Science REIT Valuation
Is JL6 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of JL6 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: JL6 (€0.31) is trading above our estimate of fair value (€0.07)
Significantly Below Fair Value: JL6 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for JL6?
Key metric: As JL6 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is JL6's PS Ratio? | |
|---|---|
| PS Ratio | 6.7x |
| Sales | UK£20.12m |
| Market Cap | UK£134.40m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 11.9x |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does JL6's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.3x | ||
DKG Deutsche Konsum REIT-AG | 1.3x | -12.7% | €141.7m |
FVI Fair Value REIT-AG | 2.3x | n/a | €54.7m |
HABA Hamborner REIT | 5x | 1.7% | €525.5m |
NHHS NorthStar Healthcare Income | 0.7x | n/a | US$148.6m |
JL6 Life Science REIT | 6.7x | 6.3% | €134.4m |
Price-To-Sales vs Peers: JL6 is expensive based on its Price-To-Sales Ratio (6.7x) compared to the peer average (2.3x).
Price to Sales Ratio vs Industry
How does JL6's PS Ratio compare vs other companies in the Global Health Care REITs Industry?
| 4 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 4 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: JL6 is expensive based on its Price-To-Sales Ratio (6.7x) compared to the Global Health Care REITs industry average (6.5x).
Price to Sales Ratio vs Fair Ratio
What is JL6's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 6.7x |
| Fair PS Ratio | 3.6x |
Price-To-Sales vs Fair Ratio: JL6 is expensive based on its Price-To-Sales Ratio (6.7x) compared to the estimated Fair Price-To-Sales Ratio (3.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €0.31 | €0.63 +104.0% | 16.8% | €0.72 | €0.48 | n/a | 3 |
| Nov ’25 | €0.35 | €0.69 +96.5% | 31.2% | €0.95 | €0.43 | n/a | 3 |
| Oct ’25 | €0.33 | €0.69 +109.7% | 31.2% | €0.96 | €0.43 | n/a | 3 |
| Sep ’25 | €0.25 | €0.69 +174.1% | 31.2% | €0.95 | €0.43 | n/a | 3 |
| Aug ’25 | €0.36 | €0.71 +97.3% | 23.9% | €0.94 | €0.53 | n/a | 3 |
| Jul ’25 | €0.38 | €0.71 +88.0% | 23.9% | €0.94 | €0.53 | n/a | 3 |
| Jun ’25 | €0.35 | €0.71 +100.6% | 23.9% | €0.93 | €0.52 | n/a | 3 |
| May ’25 | €0.44 | €0.71 +61.0% | 23.9% | €0.93 | €0.53 | n/a | 3 |
| Apr ’25 | €0.44 | €0.71 +62.1% | 23.9% | €0.94 | €0.53 | n/a | 3 |
| Mar ’25 | €0.49 | €0.97 +97.8% | 6.0% | €1.06 | €0.93 | n/a | 3 |
| Feb ’25 | €0.64 | €0.97 +53.2% | 6.0% | €1.06 | €0.93 | n/a | 3 |
| Jan ’25 | €0.69 | €0.99 +42.9% | 5.3% | €1.04 | €0.92 | n/a | 3 |
| Dec ’24 | €0.70 | €0.99 +40.8% | 5.3% | €1.04 | €0.92 | n/a | 3 |
| Nov ’24 | €0.67 | €1.01 +51.4% | 2.3% | €1.04 | €0.99 | €0.35 | 2 |
| Oct ’24 | €0.78 | €1.03 +32.9% | 2.3% | €1.05 | €1.01 | €0.33 | 2 |
| Sep ’24 | €0.72 | €1.03 +43.1% | 2.3% | €1.05 | €1.01 | €0.25 | 2 |
| Aug ’24 | €0.69 | €1.03 +48.2% | 2.3% | €1.05 | €1.01 | €0.36 | 2 |
| Jul ’24 | €0.76 | €1.03 +35.6% | 2.3% | €1.05 | €1.01 | €0.38 | 2 |
| Jun ’24 | €0.83 | €1.13 +35.4% | 14.0% | €1.29 | €0.97 | €0.35 | 2 |
| May ’24 | €0.73 | €1.13 +53.8% | 14.0% | €1.29 | €0.97 | €0.44 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Argan
€1.7b
Engages in designing, building, developing, owning, leasing, and managing logistical platforms in France.
871
€65.00
7D
-0.8%
1Y
-14.8%
Allied Properties Real Estate Investment Trust
CA$2.6b
Allied is a leading owner-operator of distinctive urban workspace in Canada's major cities.
5G8
CA$12.18
7D
0.5%
1Y
2.1%
Mercialys
€988.7m
Mercialys is one of France’s leading real estate companies.
M8Y
€10.60
7D
1.1%
1Y
23.9%